{"organizations": [], "uuid": "281a6d1c3eeab0759180f613e61e887b82410fd3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/20/globe-newswire-t2-biosystems-announces-2017-fourth-quarter-and-full-year-financial-and-operational-results-release-and-conference-call.html", "country": "US", "domain_rank": 767, "title": "T2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call Date", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.706, "site_type": "news", "published": "2018-02-20T16:00:00.000+02:00", "replies_count": 0, "uuid": "281a6d1c3eeab0759180f613e61e887b82410fd3"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/20/globe-newswire-t2-biosystems-announces-2017-fourth-quarter-and-full-year-financial-and-operational-results-release-and-conference-call.html", "ord_in_thread": 0, "title": "T2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call Date", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "lexington", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "t2 biosystems, inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LEXINGTON, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2017 fourth quarter and full-year financial and operational results after the market closes on Tuesday, March 6, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, March 6, 2018 to discuss the financial results and other business developments.\nInterested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com , in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.\nAbout T2 Biosystems:\nT2 Biosystems is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis Solution™ is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com .\nMedia Contact:\nAmy Phillips, Feinstein Kean Healthcare\namy.phillips@fkhealth.com\n412-327-9499\nInvestor Contact:\nChris Brinzey, Westwicke Partners\nchris.brinzey@westwicke.com\n339-970-2843\nSource:T2 Biosystems, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/21ce43b1-81a5-42af-8c47-c2df2e179d21", "https://www.globenewswire.com/Tracker?data=Md7sFAcCQm5BJ71Eb8-pd6lgphAo8Ao9Zro5ejkoq6Bktuq9RE_aJ3r23Bu2eHPPvyvYCOPMTu6CLcBg1LXvW8rZp74np4Pbmify2uWTdJbotyMB15JjMmWh-6WRhKo6n2ni7hpu2_6ph2qS9iCtvOYtUNJh5CUMzmMdlI3XvB60TaAtWfdh363wD-GVTD8IyI0BX8jqxYKsDoBdNmslLWfWkFmFvdOOs-UKMK5dsu2vcCx1ujB62FGbTWkOdLq-qkaWKAQWgI5QgJqcLNun9Q=="], "published": "2018-02-20T16:00:00.000+02:00", "crawled": "2018-02-20T17:20:08.011+02:00", "highlightTitle": ""}